Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
A 34-Year-Old Man with Headache, Diploplia, and Hemiparesis
Neurol 86:e28, Lincoln, M.R.,et al, 2016
Cortical Pathology in Multiple Sclerosis Patients with Epilepsy: A 3 Year Longitudinal Study
JNNP 83:49-54, Calabrese, M.,et al, 2012
Premenstrual Multiple Sclerosis Pseudoexacerbations: Role of Body Temperature and Prevention With Aspirin
Arch Neurol 63:1005-1008, Wingerchuk,D.M. &Rodriguez,M., 2006
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
An Open-Label Trial of Gabapentin Treatment of Paroxysmal Symptoms in Multiple Sclerosis Patients
Neurol 51:609-611, Solaro,C.,et al, 1998
The Phenotypic Spectrum of CADASIL:Clinical Findings in 102 Cases,
Ann Neurol 44:731-739,715, Dichgans,M.,et al, 1998
Neurologic Aspects of Inflammatory Bowel Disease
Neurol 45:416-421, Lossos,A.,et al, 1995
Treatment of Paroxysmal Symptoms in Multiple Sclerosis with Ibuprofen
Neurol 44:571-572, Khan,O.A., 1994
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
Antiphospholipid Antibody Syndrome Mimicking Multiple Sclerosis Clinically and by Magnetic Resonance Imaging
Arch Int Med 154:917-920, Scott,T.F.,et al, 1994
Uhthoff's Symptom in Disorders of the Anterior Visual Pathways
Neurol 44:1036-1038, Lepore,F.E., 1994
Lidocaine Unmasks Silent Demyelinative Lesions in Multiple Sclerosis
Neurol 42:2088-2093, Sakurai,M.,et al, 1992
Suicide and Patients with Neurologic Diseases, Methodologic Problems
Arch Neurol 49:1296-1303, Stenager,E.N.&Stenager,E., 1992
The Ocular Manifestations of Multiple Sclerosis, 2, Abnormalities of Eye Movements
JNNP 55:863-868, Barnes,D.&McDonald,W.I., 1992
Internal Capsule Plaque and Tonic Spasms in Multiple Sclerosis
Arch Neurol 48:427-429, Maimone,D.,et al, 1991
Explanation & Management of Neurological Disability
BMJ 294:1203-1205, Critchley,E.M.R.&Mitchell,J.D., 1987
Monosymptomatic Sensory Symptoms & Cerebrospinal Fluid Immunoglobulin Levels in Relation to Multiple Sclerosis
Arch Neurol 43:447-451, Kostulas,V.K.,et al, 1986
Paroxysmal Dystonia as the Initial Manifestation of Multiple Sclerosis
Arch Neurol 41:747-750, Berger,J.R.,et al, 1984
Oligoclonal IgG Bands in Cerebrospinal Fluid in Various Neurological Diseases
Ann Neurol 13:434-439, Chu,A.B.,et al, 1983
Paroxysmal Limb Hemiataxia with Crossed Facial Paresthesias in Multiple Sclerosis
JAMA 250:2843-2844, Skillrud,D.M.,et al, 1983
Clusters of Tonic Spasms as an Initial Manifestation of Multiple Sclerosis
Ann Neurol 12:494-495, Heath,P.D.,et al, 1982
Paroxysmal Symptoms as the First Manifestations of Multiple Sclerosis
JNNP 43:296-304, Twomey,J.A.,et al, 1980
Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
Catecholamines & Neurologic Diseases
NEJM 293:274, Moskowitz,M.A.,et al, 1975
Multiple Sclerosis Associated with Defects in Neuromuscular Transmission
JNNP 35:385, Patten,B.M.,et al, 1972
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Association of Very Early treatment Initiation with the Risk of Long-Term Disability in Patients with a First Demyelinating Event
Neurol 101:e1280-e1292, 549, Cobo-Calvo,A.,et al, 2023
Overlapping Anti-NMDAR Encephalitis and Multiple Sclerosis: A Case Report and Literature Review
Front Immunol doi:10.3389/Fimmun.2023.1088801, Liu,P.,et al, 2023
Diet Quality is Associated with Disability and Symptom Severity in Multiple Sclerosis
Neurol 90:e1-e11, Fitzgerald, K.C.,et al, 2018
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
High Hypothetical Interest in Physician-Assisted Death in Multiple Sclerosis
Neurol 88:1528-1534, Marrie, R.A.,et al, 2017
The Useless Hand of Oppenheim
Pract Neurol 17:464-468, Wiblin, L. & Guadagno, J., 2017
Acute Idiopathic Transverse Myelitis in Children
Neurol 84:341-349,332, Deiva, K.,et al, 2015
Relapsing-Remitting Tumefactive Demyelination
JAMA Neurol 71:366-367, Brandao, E.,et al, 2014
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013
Disability in Multiple Sclerosis
Neurol 80:1018-1024, Kister, I.,et al, 2013
Tumefactive MS Lesions under Fingolimod
Neurol 81:1654-1658, Pilz, G.,et al, 2013
Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes
Arch Neurol 69:183-190, Kinkel,R.P.,et al, 2012
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
The Differential Diagnosis of Longitudinally Extensive Transverse Myelitis
Mult Scler 18:271-285, Kitley, J.L.,et al, 2012
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011